GLP-1 receptor agonist (compounded form) Last reviewed:

Sublingual semaglutide

A needle-free compounded form of semaglutide absorbed under the tongue. Popular with needle-averse patients; absorption differs from injections, so doses are not 1:1 and evidence is far thinner.

Generic name semaglutide (compounded sublingual)
Drug class GLP-1 receptor agonist (compounded form)
Form & route Rapid-dissolve tablet (RDT) or drops held under the tongue, typically once weekly; some formulations add vitamin B6 (pyridoxine)
Typical dosing Compounded protocols commonly run 1–6 mg weekly for plain RDT forms; B6-combination formulations may use different ladders. Sublingual doses are NOT interchangeable with injection doses.
FDA status Not FDA-approved. Compounded formulation available by prescription from licensed compounding pharmacies.

What sublingual semaglutide is Sublingual semaglutide is a compounded formulation — usually a rapid-dissolve tablet (RDT) or liquid drops — held under the tongue, where some of the drug absorbs through the oral mucosa. It exists for one main reason: many people want GLP-1 results without weekly injections. It is important to be precise about what this product is and is not: - It is not an FDA-approved product. No sublingual semaglutide has gone through FDA review. - It is not the same as Rybelsus, the FDA-approved swallowed oral semaglutide tablet. - Its doses are not interchangeable with injection doses. Sublingual bioavailability is lower and more variable, which is why sublingual ladders use different (often higher-looking) milligram numbers than injections. Comparing “3 mg sublingual” to “3 mg injected” is meaningless. ## The B6 variant Some compounding pharmacies combine semaglutide with vitamin B6 (pyridoxine) in the same sublingual tablet. The rationale: B6 has evidence as an anti-nausea agent (it is a first-line treatment for pregnancy nausea), so pairing it with a GLP-1 may soften the most common side effect. A handful of telehealth programs offer this combination; it remains a compounded, non-FDA-approved product. ## What the evidence says Honestly: thin. There are no large randomized trials of sublingual semaglutide. Support comes from pharmacokinetic reasoning, small case series, and clinical experience reported by prescribers. Some patients clearly respond — appetite suppression and weight loss are observed in practice — but average results, optimal dosing, and long-term outcomes have not been characterized the way the STEP program characterized injections. If maximum certainty matters to you, injections have the data. ## Who considers it - Needle-phobic patients who would otherwise skip GLP-1 therapy entirely - People who travel constantly and find refrigerated pens impractical - Patients who had injection-site reactions ## Where it fits A small number of telehealth weight programs and compounding pharmacies offer sublingual semaglutide — NexLife is the best-known example, carrying both plain rapid-dissolve tablets and the B6-combination version alongside its injectables — see where to get GLP-1s for how to vet any of them. Expect the prescriber to be clear that this is a compounded product with different absorption; any program that markets sublingual tablets as equivalent to Wegovy is being dishonest, which tells you something about the program.

This is general information, not medical advice. Prescribing decisions belong with a licensed clinician who knows your history. Never buy GLP-1 medications from unverified sources.